CTOs on the Move

JRNI Coaching

www.jrni.co

 
JRNI Coaching provides authentic life coach training and certification in a real community with expert instructors. Join the life coaching revolution today!
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.jrni.co
  • 633, West 5th Street
    Los Angeles, CA USA 90071
  • Phone: 415.799.1316

Executives

Name Title Contact Details

Similar Companies

Stryker Sustainability Solutions

Stryker Sustainability Solutions is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Next Health

Next Health is an immunity health and wellness center specializing in IV Therapy, Cryotherapy, NAD Therapy and COVID Testing. Walk-ins are welcome.

RI International

With more than 51 programs across the U.S. and abroad, RI specializes in Crisis, Health, Recovery and Consulting Services. RI Crisis is rapidly expanding while enhancing technologies and service lines within our existing array of RRC`s(Crisis Stabilization Programs), E&Ts (Involuntary & Court-ordered Treatment), and Crisis Respites.

Baker Dental Corp

Baker Dental Corp is a Hawthorn Woods, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.